Drug Profile
Buprenorphine/granisetron controlled release - Camurus/Braeburn
Alternative Names: BB0417; CAM 2058Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Camurus
- Class Analgesics; Antiemetics; Azabicyclo compounds; Cyclopropanes; Indazoles; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Postoperative nausea and vomiting; Postoperative pain
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting in Sweden (SC, Controlled release)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting(Prevention) in Sweden (SC, Controlled release)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Postoperative-pain in Sweden (SC, Controlled release)